/l and 40% blasts were present in the bone marrow. Cytogenetic analysis was not available at that time. A diagnosis was made of acute myelomonocytic leukaemia secondary to previous treatment with razoxane for severe psoriasis, which had caused multiple episodes of erythroderma and frequent hospitalisation over the previous 20 years. This drug had been discontinued 3 months previously due to case reports of secondary AML with its use. Remission induction was with the standard DAT 3 þ 10 regime. Complete remission was documented after this first course, which was followed by four courses of DAT 1 þ 5 maintenance therapy. A T-cell-depleted allogeneic transplant was carried out in August 1985 using marrow harvested from an HLA-identical sibling. Conditioning therapy was with cyclophosphamide and total body irradiation. Resolution of psoriasis was noted at this stage. In October 1986, there was relapse of AML with Hb 8.3 g/dl, WBC 23.3 Â 10 9 /l, plts 26 Â 10 9 /l and 30% blasts in the bone marrow. It was decided to undertake a T-cell replete transplant from the same donor. A reduced intensity conditioning regime was used consisting of cytosine arabinoside 2.25 g/m 2 i.v. in divided doses daily for 2 days followed by cyclophosphamide 60 mg/kg once daily i.v. for 2 days. The post transplant period was uneventful. Neutrophils reached 1.0 Â 10 9 /l at day 35 and plts reached 50 Â 10 9 /l at day 49. There was no evidence of acute or chronic GVHD and cyclosporine was withdrawn at 10 months post transplant.
The patient is now in complete remission with no evidence of a psoriatic rash 17 years post nonmyeloablative transplant. At a recent outpatient review, full blood count showed Hb 14.6 g/dl, WBC 7.8 Â 10 9 /l and plts 267 Â 10 9 /l. In the interim, he has been diagnosed with renal artery stenosis resulting in hypertensive renal impairment. He has also developed ischaemic heart disease, suffering two myocardial infarctions and requiring coronary angioplasty.
Advances in conventional allogeneic transplantation have been hindered by the toxicity associated with conditioning therapy. With the knowledge that the stem cell graft itself exerts an important immunomodulatory graft-versus-leukaemia (GVL) effect, strategies such as nonmyeloablative transplantation and donor lymphocyte infusion (DLI) have been devised in an attempt to utilise this phenomenon, rather than eradicating host malignant cells with high dose chemoradiotherapy. In theory, reduced intensity conditioning might lead to a reduction in transplant-related mortality, allowing its use in a wider spectrum of patients.
DLI has been successfully used in chronic phase chronic myeloid leukaemia, but results have been less favourable in acute leukaemia where complete remission rates of less than 30% are seen 1 and doubts remain as to its long-term effectiveness in particular its ability to prevent relapse. 2 Although allogeneic transplantation has been shown to be of benefit in relapsed and refractory AML attempts at stem cell transplantation for patients in frank relapse of leukaemia have yielded poor results with less than 10% long-term disease-free survival. 3 It can therefore be seen that the outlook was poor for a successful outcome in this case. A T-cell-depleted transplant, which appeared to cure his psoriasis, was not sufficient to maintain a remission of his AML. It is likely that the initial myeloablative transplant induced host-versus-graft unresponsiveness, so that when a DLI equivalent procedure was carried out using T-cell replete marrow, a second complete remission was achieved which is ongoing at 17 years. Although the T cells in the graft are responsible for the development of GVHD, it is worth noting that a second remission was achieved without the development of GVHD. This may provide further evidence that the GVL response and GVHD are not inextricably linked.
This man developed secondary AML subsequent to razoxane treatment. The drug razoxane is an inhibitor of topoisomerase II that has been widely used in the past in the treatment of psoriasis. Its use increased in the early 1980s after impressive response rates had been seen in patients intolerant of methotrexate. However, cases of AML were soon reported as a cause for concern. 4 Psoriasis is an immune-mediated chronic skin disorder. T-lymphocytes are known to be involved in its pathogenesis 5 and immunosuppressants have been used in its treatment for many years. Activated T cells present in the cutaneous lesions release cytokines such as TNFa, thus attracting other immune cells into the lesions. Resolution of psoriasis with transplantation has been reported previously. 6, 7 While allogeneic transplantation has been successful, the associated 20-25% mortality rate 8 is likely to preclude it as a viable therapy for most patients. Autologous transplantation, with a mortality rate of 3-5%, has been shown in animal models of psoriasis to have curative potential and has been used in carefully selected patients with psoriatic arthritis. 9 This approach to treating severe autoimmune disease with increased safety is attractive and trials are underway in many conditions such as multiple sclerosis, lupus, rheumatoid disease and haematological conditions, including autoimmune haemolytic anaemia. 10 In conclusion, this report illustrates that immunotherapy is potentially curative in cases of relapsed or refractory
